Raffaele De Caterina (Chair Director and School of Specialization, David Moliterno (Professor of Medicine in the Department of Interna, Steen Kristensen (Consultant Cardiologist and Head of the Cardiovas

The Esc Textbook of Thrombosis

• Gebundenes Buch

Produktbeschreibung

The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications portfolio, it is informed by the work of the ESC's Working Group on Thrombosis.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• The European Society of Cardiology Series
• Verlag: Oxford University Press
• Seitenzahl: 400
• Erscheinungstermin: 16. Januar 2024
• Englisch
• Abmessung: 274mm x 236mm x 30mm
• Gewicht: 1222g
• ISBN-13: 9780192869227
• ISBN-10: 0192869221
• Artikelnr.: 69191129

Autorenporträt

Raffaele De Caterina is Professor of Cardiology at the University of Pisa, and Director, University Cardiology Division, at Pisa University Hospital. He is also Scientific Advisor for the "G. Monasterio" Foundation, Pisa, Italy. He has been Vice-President of the European Society of Cardiology (2008-2010) and President (2009-2013) of the International Society on Nutrigenetics/Nutrigenomics. He is the past-Editor-in-Chief of the journal Vascular Pharmacology, curent Executive Editor of European Heart Journal, and author of >600 peer-reviewed manuscripts. Major research interests: Cardiovascular Pharmacology, Atrial Fibrillation, Coronary Artery Disease, Cardiovascular Thrombosis, Nutrigenetics and Nutrigenomics. David J. Moliterno, MD (FESC, FACC, FSCAI, FAHA) is a Professor at the University of Kentucky. He was an attending cardiologist at the Cleveland Clinic for 10 years before joining the University of Kentucky, where he was chief of cardiovascular medicine and subsequently chair of internal medicine. Dr. Moliterno has been a visiting professor or lecturer in more than 30 countries. He is the author of over 400 publications and editor of 8 textbooks. He has been the primary author of publications in BMJ, Circulation, EHJ, JACC, JAMA, Lancet, and NEJM. He is currently the Editor-in-Chief for the JACC: Cardiovascular Interventions and serves on the advisory board of the US FDA. As a clinical researcher, Dr. Moliterno has been a leader in numerous multinational investigational studies. Collectively, these studies have involved over $1 billion in clinical trial research. His primary interests involve acute coronary syndromes, antithrombotic therapies, and interventional cardiology. Steen Dalby Kristensen is a professor and interventional cardiologist at Aarhus University Hospital, Denmark. Scientific/clinical interests: Thrombosis and anti-thrombotic treatment. Coronary artery disease and acute cardiac care. Percutaneous coronary interventions. Author of more than 365 scientific papers and 17 book chapters. Editor of 5 textbooks. Editor of European Heart Journal, Thrombosis and Haemostasis and European Heart Journal: Acute Cardiovascular Care. Invited speaker in more than 40 different countries. Supervisor of 15 PhD students. Chair of international research committees for evaluation of scientific applications in Germany and Spain. Evaluator of grants in Sweden, Norway, Italy, Germany, Spain, Finland and Denmark. Has been ESC Vice-president, ESC secretary/treasurer and leader of several key ESC initiatives, ESC committees and working groups. Past President of the Danish Society of Cardiology

Inhaltsangabe

* 1: Raffaele De Caterina, David J. Moliterno, and Steen Dalby
Kristensen: Introduction
* Section 1: Pathophysiology of thrombosis
* 2: Lina Badimon and Gemma Vilahur: Arterial thrombosis:
Pathophysiological background
* 3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van
Es: Venous thrombosis and thromboembolism: Pathophysiological
background
* 4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis
and thromboembolism in atrial fibrillation: Pathophysiological
background
* 5: Tobias Geisler: Thrombosis on foreign surfaces and devices
* Section 2: Clinical pharmacology of antithrombotic drugs
* 6: Carlo Patrono and Bianca Rocca: Aspirin
* 7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
* 8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol,
GP IIb/IIIa inhibitors, and PAR-1 antagonists
* 9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin,
bivalirudin, argatroban and danaparoid
* 10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
* 11: Alex Benz and Stefan Hohnloser: Dabigatran
* 12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan
Wallen: Oral factor Xa (FXa) inhibitors
* 13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral
factor XIa and FXIIa inhibitors
* 14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and
ancillary antithrombotic therapies
* Section 3: Therapeutic strategies
* 15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti:
Antithrombotic strategies in primary cardiovascular prevention
* 16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in
patients undergoing elective percutaneous coronary interventions and
in chronic coronary syndromes without interventions
* 17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno,
Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy
in ST-elevation acute myocardial infarction and non-ST elevation
acute coronary syndromes
* 18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno:
Anti-thrombotic therapy for patients with prosthetic valves and
during structural percutaneous interventions
* 19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom:
Antithrombotic therapies in ischaemic stroke
* 20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and
Erik Lerkevang Grove: Antithrombotic therapy in patients with patent
foramen ovale (PFO), PFO closure, left ventricular mural thrombus,
atrial thrombus, and catheter-related thrombosis
* 21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation:
current and forthcoming antithrombotic therapies
* 22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous
thromboembolism: prophylaxis and treatment
* 23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck:
Biomarker-based risk stratification in cardiovascular disease
* Section 4: Special situations
* 24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in
inherited or acquired thrombophilia
* 25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao:
Prevention and treatment of bleeding related to antithrombotic drug
treatment
* 26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M.
Siller-Matula: Management of patients treated with antithrombotic
drugs undergoing surgery
* 27: Alexander C Fanaroff, Renato D Lopes, John H Alexander:
Antithrombotic therapy in patients with atrial fibrillation and
recent coronary stenting, with or without an acute coronary syndrome
* 28: Stefan Agewall, Vanessa Roldán, and Francisco Marín: Prevention
and treatment of venous and arterial thrombosis in patients with
specific conditions: diabetes, renal insufficiency, thrombophilia and
pregnancy
* 29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno:
Antithrombotic agents and drug-drug interactions
* 30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and
Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring
individual variation and monitoring
* 31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug
development, clinical trials, and regulatory requirements